Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
mitochondrial fragmentation
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "mitochondrial fragmentation" in MCE Product Catalog:
Cat. No.: HY-172942
CAS No.: 2629218-24-0
Research Areas:
Cardiovascular Disease Infection Neurological Disease Cancer
SP11 is a mitochondrial fission protein 1 (Fis1) inhibitor with an IC50 of 9.4 μM. SP11 binds only to activated Fis1 by engaging Cys41. SP11 preserves mitochondrial integrity and function during oxidative stress, inhibits hydrogen peroxide-induced mitochondrial ROS production, mitochondrial fragmentation, and Drp1 mitochondrial translocation. SP11 can be used for the research of parkinson’s disease .
Cat. No.: HY-148009
CAS No.: 2260669-35-8
Synonyms: 16:0-18:1 Cardiolipin sodium
Target:
Research Areas:
Cardiolipin (16:0/18:1/16:0/18:1) (16:0-18:1 Cardiolipin) sodium is a di-saturated mitochondrial-specific anionic phospholipid sodium salt containing the long-chain fatty acid palmitic acid (HY-N0830) and the monounsaturated fatty acid oleic acid (HY-N1446). Cardiolipin (16:0/18:1/16:0/18:1) sodium undergoes in-source fragmentation via diglyceride (DG)-H2O fragment formation and (DG-H2O) fragment loss pathways. Cardiolipin (16:0/18:1/16:0/18:1) sodium can be used in the synthesis of lipid nanodiscs for application in in situ mass spectrometry .
Cat. No.: HY-112624K
CAS No.: 9004-54-0
Synonyms: Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)
Target:
Research Areas:
MFN2 agonist-1 is an allosteric agonist of mitofusin 2 (MFN2) with an EC50 of 3 nM. MFN2 agonist-1 mimics the MFN2 HR1 peptide to compete for HR2, disrupt the HR1-HR2 autoinhibitory interaction, stabilize the open conformation of MFN2, and promote GTP hydrolysis and mitochondrial fusion. MFN2 agonist-1 acts in a manner dependent on endogenous MFN1 or MFN2, and does not impair cell viability. MFN2 agonist-1 reverses mitochondrial fragmentation, depolarization, aggregation and axonal transport defects, restores bidirectional movement and improves enhanced autophagy. MFN2 agonist-1 is used in studies related to Charcot-Marie-Tooth disease type 2A, Alzheimer's disease, Parkinson's disease and Huntington's disease .
Cat. No.: HY-164566
CAS No.: 348145-43-7
Target:
Research Areas:
POSH-IN-2 (MIDI), a mitochondrial division inhibitor, is a DRP1 inhibitor that potently blocks mitochondrial fragmentation induced by cellular stresses and genetic mitochondrial lesions. POSH-IN-2 covalently interacts with DRP1-C367 to target DRP1 interaction with multiple receptors .
Research Areas:
Coenzyme Q2 is a benzoquinone electron carrier in the mitochondrial electron transport chain and a p53-dependent apoptosis inducer. Coenzyme Q2 induces p53 phosphorylation at Ser15, promoting p53 accumulation and functional activation. Coenzyme Q2 induces ROS generation, caspase-3 activation, DNA fragmentation, phosphatidylserine externalization, mitochondrial permeability transition pore opening, and oxidative phosphorylation uncoupling. Coenzyme Q2 inhibits Complex I, Complex III, and Complex IV activities, disrupting electron transport and membrane potential generation. Coenzyme Q2 induces excessive mitochondrial proton leak in forebrain mitochondria. Coenzyme Q2 causes loss of righting reflex in mice, accompanied by slow-wave delta EEG activity and reversible loss of wakefulness. Coenzyme Q2 inhibits lipid peroxidation and scavenges superoxide radicals. Coenzyme Q2 is used in research on leukemia, myocardial ischemia-reperfusion injury, and mitochondrial encephalomyopathy .
Cat. No.: HY-177306
Opitor-0 is a OPA1 GTPase inhibitor with an IC50 of 3.0 μM. Opitor-0 disrupts mitochondrial cristae structure and respiratory efficiency, induces mitochondrial fragmentation, enhances cBID-mediated cytochrome c release, and restores the sensitivity of triple-negative breast cancer (TNBC) cells to ABT-737 (HY-50907). Opitor-0 selectively reduces the migration and proliferation capacities of metastatic breast cancer cells, and induces cell death and apoptosis. Opitor-0 can be used in studies related to metastatic breast cancer and triple-negative breast cancer .
Cat. No.: HY-139012
CAS No.: 2584411-87-8
Target:
Research Areas:
RC574 is a GPx1 and GPx4 modulator that increases GPx1 protein levels and enzyme activity and protects cells against RSL3-induced GPx4 inactivation and ferroptosis. RC574 inhibits glutamate-induced ferroptosis/oxytosis, mitochondrial superoxide anion production, mitochondrial membrane hyperpolarization, oxidant production, and mitochondrial fragmentation. RC574 protects primary cortical neurons against glutamate challenge and inhibits mitochondrial superoxide anion production while increasing antioxidant enzyme activity. RC574 ameliorates motor-related behavioral deficits and reduces reactive astrocytes in the striatum in a rat model of ischemic stroke. RC574 can be used in research on neurodegenerative diseases and ischemic stroke .
Cat. No.: HY-174377
Target:
Androgen Receptor p38 MAPK Caspase Cytochrome P450 Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Mitochondrial Metabolism GLUT
Research Areas:
PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors .
Cat. No.: HY-171184
CAS No.: 1140627-77-5
EAPB0503 is a quinoline compound with anti-tumor activity, showing strong cytotoxicity against melanoma cells in vitro (IC50=200 nM). EAPB0503 can induce specific cell cycle arrest in mitosis of CML cells and directly activate apoptosis, leading to an increase in the G0 cell population, disruption of mitochondrial membrane potential, PARP cleavage, and DNA fragmentation. EAPB0503 also reduces the levels of BCR-ABL protein .
Cat. No.: HY-178099
Target:
Research Areas:
Apoptosis inducer 45 is an apoptosis inducer. Apoptosis inducer 45 is cytotoxically active against the MCF-7 cell line. Apoptosis inducer 45 elicits MCF-7 cell apoptosis via the mitochondrial pathway (increases the Bax/Bcl-2 ratio) by activating cleavage of caspase-9, thereby inducing the fragmentation of DNA repair protein PARP. Apoptosis inducer 45 also can induce caspase-8 cleavage, subsequently initiating cleavage of caspase-3 and its downstream protein PARP to culminate in the extrinsic apoptosis. Apoptosis inducer 45 can be used in the research of breast cancer .
Cat. No.: HY-159518
CAS No.: 2959444-40-5
Research Areas:
ROS inducer 4 (compound TE3) is a mitochondrial inhibitor. ROS inducer 4 causes a series of mitochondria-related physiological changes in tumors, such as mitochondrial fragmentation, explosive generation and accumulation of ROS, decreased mitochondrial membrane potential, decreased ATP content, and activation of ROS-mediated apoptotic signaling in mitochondria .
Cat. No.: HY-121642
CAS No.: 1169831-01-9
SL-017 is a novel photoacoustic sensitizer and a derivative of photofrin B. It can be taken up by cells to the maximum extent within 30 minutes and is mainly localized in mitochondria. After being activated by visible light or ultrasound, SL-017 can significantly increase the production of reactive oxygen species (ROS). Low concentrations of SL-017 can rapidly cause the loss of mitochondrial membrane potential. SL-017 can also cause mitochondrial fragmentation, a process that occurs after the loss of membrane potential. Epoxyeicosatrienoic acids (EETs) can alleviate the loss of mitochondrial membrane potential caused by SL-017, but the antioxidant ascorbic acid has no such effect. These characteristics indicate that SL-017 mainly targets mitochondria and exerts its cytotoxic effect by triggering the collapse of mitochondrial membrane potential, generating ROS, and causing mitochondrial fragmentation. As a novel photoacoustic sensitizer, SL-017 has potential application value in photodynamic therapy and sonodynamic therapy.
Cat. No.: HY-N8617
CAS No.: 135247-94-8
Cat. No.: HY-176775
CAS No.: 1423018-61-4
Research Areas:
TPP-IOA is a cytochrome c peroxidase inhibitor. TPP-IOA inhibits apoptosis by preventing cardiolipin oxidation and cytochrome c release to the cytosol. TPP-IOA disrupts oxidative phosphorylation in isolated mitochondria. TPP-IOA inhibits cell death in SH-SY5Y cells grown in glucose, but not galactose. TPP-IOA causes mitochondrial depolarization and network fragmentation. TPP-lOA mitigates radiation induced death in mice .
Cat. No.: HY-N3055
CAS No.: 31685-80-0
Category:
Target:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
